ATE455793T1 - Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen - Google Patents

Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Info

Publication number
ATE455793T1
ATE455793T1 AT02721722T AT02721722T ATE455793T1 AT E455793 T1 ATE455793 T1 AT E455793T1 AT 02721722 T AT02721722 T AT 02721722T AT 02721722 T AT02721722 T AT 02721722T AT E455793 T1 ATE455793 T1 AT E455793T1
Authority
AT
Austria
Prior art keywords
meningococcal
epitopes
monoclonal antibodies
molecular mimetics
antibodies against
Prior art date
Application number
AT02721722T
Other languages
German (de)
English (en)
Inventor
Dan Granoff
Gregory Moe
Rino Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Childrens Hosp Oak Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Childrens Hosp Oak Res Inst filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE455793T1 publication Critical patent/ATE455793T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02721722T 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen ATE455793T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28455401P 2001-04-17 2001-04-17
US32683801P 2001-10-03 2001-10-03
PCT/US2002/011501 WO2002083711A2 (en) 2001-04-17 2002-04-11 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies

Publications (1)

Publication Number Publication Date
ATE455793T1 true ATE455793T1 (de) 2010-02-15

Family

ID=26962673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721722T ATE455793T1 (de) 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Country Status (10)

Country Link
US (1) US7534444B2 (https=)
EP (1) EP1379272B1 (https=)
JP (3) JP2004529643A (https=)
CN (1) CN1306956C (https=)
AT (1) ATE455793T1 (https=)
AU (1) AU2002252638A1 (https=)
CA (1) CA2439428C (https=)
DE (1) DE60235155D1 (https=)
RU (1) RU2322451C2 (https=)
WO (1) WO2002083711A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP2270173B1 (en) 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2000278267A1 (en) * 2000-09-01 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2005023295A2 (en) * 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
AU2005214061B2 (en) * 2004-02-18 2010-02-04 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
DE102004023906A1 (de) * 2004-05-13 2005-12-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von chemischen Mikroarrays
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
DE112009000608B4 (de) 2008-04-18 2017-12-28 Denso Corporation Kälteerzeugungszyklusvorrichtung eines Ejektor-Typs
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
JP2015517089A (ja) * 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
EP0145359B1 (en) 1983-11-21 1991-01-16 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
US5128460A (en) * 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
DE69019164T2 (de) 1989-12-14 1995-09-07 National Research Council Of Canada, Ottawa, Ontario Verbessertes meningokokkale polysaccharidkonjugatvakzin.
RU2068270C1 (ru) * 1993-01-13 1996-10-27 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Антиген менингококков группы в
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ES2166097T5 (es) 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
CA2301942C (en) 1997-08-27 2011-05-31 Chiron Corporation Molecular mimetics of meningococcal b epitopes
EP2261352A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP4812942B2 (ja) 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
JP2003518363A (ja) * 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
CN101033467A (zh) * 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.

Also Published As

Publication number Publication date
AU2002252638A1 (en) 2002-10-28
CA2439428C (en) 2012-01-24
EP1379272A4 (en) 2005-12-14
CN1306956C (zh) 2007-03-28
JP2004529643A (ja) 2004-09-30
CN1602204A (zh) 2005-03-30
EP1379272B1 (en) 2010-01-20
CA2439428A1 (en) 2002-10-24
US7534444B2 (en) 2009-05-19
RU2322451C2 (ru) 2008-04-20
WO2002083711A3 (en) 2003-11-06
DE60235155D1 (de) 2010-03-11
JP5215275B2 (ja) 2013-06-19
RU2003133300A (ru) 2005-04-20
JP2010011868A (ja) 2010-01-21
US20040013686A1 (en) 2004-01-22
EP1379272A2 (en) 2004-01-14
WO2002083711A2 (en) 2002-10-24
JP2008259503A (ja) 2008-10-30

Similar Documents

Publication Publication Date Title
ATE455793T1 (de) Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
EP2277537A3 (en) Neisseria meningitidis conjugate combination vaccine
ATE505478T1 (de) Molekular-mimetika von meningokokkalen b epitopen
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
JP2007533729A5 (https=)
BR0015961A (pt) Antìgeno de neisseria de 85kda
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
EP1725872B8 (en) Analysis of saccharide vaccines without interference
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
BR9906927A (pt) Proteìnas de neisseria meningitidis
FR17C1044I2 (fr) Nouvelles compositions immunogenes pour la prevention et le traitement de la meningite a meningocoques
BRPI0410423A (pt) processo de imunogenicidade melhorada para vacinação meningocócica
DK1587537T3 (da) Injicerbare vacciner mod multiple meningococ-serogrupper
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
Plested et al. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B
CY1111114T1 (el) Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις
NO902280D0 (no) Ny poroes farmasoeytisk form og fremstilling derav.
ATE308992T1 (de) Attenuierte bakterien verwendbar als impstoffe
Michaelsen et al. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria
DE60036692D1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
BRPI0500090A (pt) Composição de acabamento
TR200003467T2 (tr) Neisseria meningitidis antijenik polipeptidler, mütekabil polinükleotidler ve koruyucu antikorlar
DE60333027D1 (de) Antigene zusammensetzungen zur immunisierung nichtmenschlicher säuger gegen streptococcus equi
Luijkx et al. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties